Access to mugs should be on the clinical questionnaire.

I would stop trying to convey how bad it is and start saying what you want them to do.

Three questions kill most of the confidence in a thread like this: sample size, blinding, who paid.

Filing early beats arguing later. And ask for the reference number, always.

Same shape here, different drug. The thing that helped was documenting the refusal rather than re-arguing it. They refer rather than write.

My rule, after years of this: if it cannot survive being written down with the numbers attached, it is marketing.

How do you tell the difference between the drug working and just a good week?

Fees like that are charged by the carrier, not the state, which is why they are hard to contest.